Clinical Ink lands growth equity from Ardan, GI Partners at $500M+ valuation
What's the deal? Clinical Ink, a Winston-Salem, North Carolina-based clinical-trial technology company, has raised growth equity from healthcare-technology investor Ardan EquityDealroom has a profile for this one. Try Dealroom → and existing backer GI PartnersDealroom has a profile for this one. Try Dealroom →. Both firms made new equity investments in a co-control partnership. The amount and terms were not disclosed.
What the company does: Clinical Ink runs an eSource platform that captures clinical-trial data for pharmaceutical sponsors and contract research organisations (CROs). Its tools span electronic clinical outcome assessments (eCOA), direct data capture, eConsent, telehealth visits, wearable sensors, and digital biomarkers.
What's the money for? The company plans to expand into more therapeutic areas and scale its platform globally. It is also building newer products, including GlucoseReady for diabetes trials, SPUR for medication adherence, and the Kaitality application for drug adherence and weight-management studies.
What's the valuation? Terms were not disclosed, but Axios reported before the announcement that the deal values Clinical Ink at more than $500 million.
GI Partners, which has backed Clinical Ink since 2020, cited the company's growth since its first investment. "We are well-positioned to capitalise on the industry's increasing complexity," said Dave Kreter, managing director at GI Partners. Noah Lewis of Ardan Equity said Clinical Ink is "at a pivotal moment" with a broad platform and expanding roster of pharmaceutical sponsors.
The signal: The deal fits a wider consolidation push in clinical-trial technology. Signant Health acquired wearable-data specialist Ametris in May 2026, and Thermo Fisher completed its $8.875 billion purchase of ClarioDealroom has a profile for this one. Try Dealroom → in March — both aimed at bundling patient-reported outcomes and digital endpoints into broader platforms. Clinical Ink's new backing signals that investors still see room for independent players to scale in that race.
Read more: third-news.com, Axios
Image credit: MDGovpics
